Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director · CEO | May 31, 2025 | June 03, 2025 |
| Nasus Pharma LtdNSRX · Entity 7254 | Director · Chief Executive Officer | July 27, 2026 | July 31, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, North America Commercial | March 04, 2021 | March 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date May 31, 2025 · Filed June 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,955.462 |
Ending reported balance
After 2025-05-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-31 · Exercise / conversion · Acquired 166,665 · Balance 178,371.462 Row 2 · 2025-05-31 · Tax withholding · Disposed 49,416 · Balance 128,955.462 F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-05-31 | Direct | 333,335 |
Reported balance
After 2025-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-31 · Exercise / conversion · Disposed 166,665 · Balance 333,335 F2: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3: One-third of these restricted stock units vests on each of May 31, 2025, 2026 and 2027, assuming continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
F3: One-third of these restricted stock units vests on each of May 31, 2025, 2026 and 2027, assuming continued employment through the applicable vesting date.
F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Nasus Pharma Ltd
Report date July 27, 2026 · Filed July 31, 2026
This filing explicitly reported no securities owned.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 04, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,868.486 |
Last balance in matching sequence
After 2021-03-05 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2021-03-04 · Sale · Disposed 703 · Balance 14,868.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2021-03-04 · Exercise / conversion · Acquired 18,905 · Balance 33,773.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 3 · 2021-03-04 · Sale · Disposed 7,469 · Balance 26,304.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5100 to $10.6900, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2021-03-05 · Sale · Disposed 11,436 · Balance 14,868.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5000 to $10.5775, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 37,811 |
Reported balance
After 2021-03-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-04 · Exercise / conversion · Disposed 18,905 · Balance 37,811 F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 109,315 |
Reported balance
After 2021-03-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-05 · Grant · Acquired 109,315 · Balance 109,315 F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8: Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5100 to $10.6900, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5000 to $10.5775, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.
F8: Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2025 Filed Jun 3, 2025 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionRestricted Stock Units · Derivative | 166,665 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056049 · tm2516886-1_4seq1.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,335 Underlying: Common Stock · 166,665 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: One-third of these restricted stock units vests on each of May 31, 2025, 2026 and 2027, assuming continued employment through the applicable vesting date. Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Tax withholdingCommon Stock | 49,416 | $0.66 | $32,827.05 |
DisclosureSEC source: 0001104659-25-056049 · tm2516886-1_4seq1.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,955.462 F1 · shares: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionCommon Stock | 166,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056049 · tm2516886-1_4seq1.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,371.462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (Right to Buy) · Derivative | 755,525 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001104659-25-015756 · tm257086-1_4seq1.xml · derivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755,525 Underlying: Common Stock · 755,525 shares Expires 2035-02-18 F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment through the applicable vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015756 · tm257086-1_4seq1.xml · derivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-02-18 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment through the applicable vesting date. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 19:43 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | PurchaseCommon Stock | 11,706.462 | $0.85 | $9,950.49 |
DisclosureSEC source: 0001104659-24-119663 · tm2428579-1_4seq1.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,706.462 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple same-way transactions on November 14, 2024 at prices ranging from $0.84 to $0.85 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock purchased at each separate price. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:01 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (Right to Buy) · Derivative | 1,800,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001104659-24-068356 · tm2416400-2_4seq1.xml · derivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800,000 Underlying: Common Stock · 1,800,000 shares Expires 2034-05-31 F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment through the applicable vesting date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:01 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-068356 · tm2416400-2_4seq1.xml · derivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-05-31 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment through the applicable vesting date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 109,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018526 · doc4.xml · derivative · entry 6 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,315 Underlying: Ordinary Shares · 109,315 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025. F8 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 11,436 | $10.54 | $120,580.04 |
DisclosureSEC source: 0001209191-21-018526 · doc4.xml · nonDerivative · entry 4 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,868.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5000 to $10.5775, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 18,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018526 · doc4.xml · derivative · entry 5 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,811 Underlying: Ordinary Shares · 18,905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 7,469 | $10.57 | $78,918.20 |
DisclosureSEC source: 0001209191-21-018526 · doc4.xml · nonDerivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,304.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5100 to $10.6900, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 18,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018526 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,773.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 703 | $10.80 | $7,592.40 |
DisclosureSEC source: 0001209191-21-018526 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,868.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017764 · doc4.xml · derivative · entry 4 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F7 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 463 | $10.86 | $5,029.38 |
DisclosureSEC source: 0001209191-21-017764 · doc4.xml · nonDerivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,571.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.835 to $10.910, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017764 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,034.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 15,085 | $10.85 | $163,601.35 |
DisclosureSEC source: 0001209191-21-017764 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,868.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.800 to $10.870, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 63,278 | $10.93 | $691,350.12 |
DisclosureSEC source: 0001209191-21-015852 · doc4.xml · nonDerivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,953.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.905 to $10.980, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,849 | $10.83 | $106,672.55 |
DisclosureSEC source: 0001209191-21-015852 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,231.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015852 · doc4.xml · derivative · entry 4 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,805 Underlying: Ordinary Shares · 24,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 24,934 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 24,937 vesting on February 28, 2024. F7 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 24,934 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 24,937 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015852 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,080.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009639 · doc4.xml · derivative · entry 5 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,121 Underlying: Ordinary Shares · 16,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 16,720 | $12.69 | $212,252.04 |
DisclosureSEC source: 0001209191-21-009639 · doc4.xml · nonDerivative · entry 4 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,146.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,974 | $12.69 | $50,447.94 |
DisclosureSEC source: 0001209191-21-009639 · doc4.xml · nonDerivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,866.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 67,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009639 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,840.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009639 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,988.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:37 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020165 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:37 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 470 | $7.16 | $3,366.85 |
DisclosureSEC source: 0001209191-20-020165 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,868.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:37 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020165 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,338.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016461 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 463 | $11.37 | $5,262.37 |
DisclosureSEC source: 0001209191-20-016461 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,159.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.8900 to $11.7400, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016461 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,622.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 99,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014853 · doc4.xml · derivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,739 Underlying: Ordinary Shares · 99,739 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 24,934 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 24,937 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 24,934 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 24,937 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,799 | $12.27 | $58,883.73 |
DisclosureSEC source: 0001209191-20-008166 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,456.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008166 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,241 Underlying: Ordinary Shares · 16,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008166 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,255.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050266 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,241 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 1,241 vesting on each of September 18, 2018 and September 18, 2019. F5 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 1,241 vesting on each of September 18, 2018 and September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 494 | $7.83 | $3,868.66 |
DisclosureSEC source: 0001209191-19-050266 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,135.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.82 to $7.835, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-050266 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,179 | $16.63 | $19,600.99 |
DisclosureSEC source: 0001209191-19-020163 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020163 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,179 Underlying: Ordinary Shares · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020163 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,567.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019332 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 738 vesting on each of March 12, 2018 and March 12, 2019. F4 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 738 vesting on each of March 12, 2018 and March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 738 | $15.67 | $11,568.08 |
DisclosureSEC source: 0001209191-19-019332 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6600 to $15.6911, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-019332 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,126.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,166 | $16.88 | $19,685.93 |
DisclosureSEC source: 0001209191-19-016093 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 56,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017234 · doc4.xml · derivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,716 Underlying: Ordinary Shares · 56,716 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016093 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,332 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F4 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016093 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,554.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.